PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 70089

Title: Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis (TEN) in a patient with metastatic liver cancer: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05146264

Position: Associate Editor

Academic degree: MBBS, MD

Professional title: Assistant Professor, Research Assistant Professor

Reviewer’s Country/Territory: India

Author’s Country/Territory: China

Manuscript submission date: 2021-07-25

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-11-02 04:40

Reviewer performed review: 2021-11-06 05:34

Review time: 4 Days

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ ] Yes                      | [ Y] No                        |
SPECIFIC COMMENTS TO AUTHORS
Thank you authors for submitting your manuscript to The World Journal of Clinical Cases. It is a written article and adds information to the existing literature.
Name of journal: World Journal of Clinical Cases

Manuscript NO: 70089

Title: Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis (TEN) in a patient with metastatic liver cancer: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05429043

Position: Editorial Board

Academic degree: PhD

Professional title: Assistant Professor

Reviewer’s Country/Territory: India

Author’s Country/Territory: China

Manuscript submission date: 2021-07-25

Reviewer chosen by: Xin Liu (Online Science Editor)

Reviewer accepted review: 2021-11-30 09:29

Reviewer performed review: 2021-12-08 06:04

Review time: 7 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SPECIFIC COMMENTS TO AUTHORS

The article entitled as “Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis (TEN) in a patient with metastatic liver cancer: A case report” by Huang KK et al. describe TEN following combination therapy with a PD-1 inhibitor and lenvatinib. The topic looks very interesting. I have a few concerns:

1. Please mention the rationale for choosing the therapy as the usual therapy is Sorafenib.
2. Is the same side effect reported in any cancer condition?
3. Have the patient look into only person?
4. Ethical clearance: no is needed as suggested by the journal.
5. I have found some technical errors with the file: eg: some words are combined without any separation. May be it is software issue. Please correct it.